The Biden Administration will introduce at least six notable changes impacting pharma in 2021. Among his top priorities, Biden will move toward negotiating Medicare drug prices using an international index as a price ceiling, and impose launch and biosimilar price limits. HeÕs supporting drug import initiatives at the state level; intends to eliminate the existing tax deduction for drug advertising costs; and supports proposals to crack down on delay tactics used to block development of generics and biosimilars.


Related Reports

Medicaid Analyzer | 2021 | National MCO Analyzer

The Biden administration has begun pulling back Medicaid changes advanced by Trump officials that would restrict eligibility, add wellness requirements, allow block grants, or increase recipient co...

View Details

Cigna | 2021 | National MCO Analyzer

CignaÕs base of large self-insured employer groups translates into a membership that is mostly urban and fully employed. It works to tailor its care-management and service offerings and bene...

View Details

Federal Employees Health Benefit Program | 2020 | National MCO Analyzer Trends

Enrollment in the Federal Employee Health Benefits Program is most heavily concentrated in the Washington, D.C., market and California, driving enrollment to program carriers including CareFirst, K...

View Details

Premera Blue Cross | 2021 | National MCO Analyzer Brief

As the COVID-19 pandemic emergency slowly resolves, watch for Premera Blue Cross to return its attention to behavioral health to improve health outcomes for patients. For example, in April 2021, th...

View Details